Axel Bolte
CIK 1579247 · Chief Executive Officer · last filed 2025-07-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
PTCT price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
100 CORPORATE COURT
SOUTH PLAINFIELD, NJ 07080
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Inozyme Pharma, Inc. (INZY) Delisted | Director | 423,926 | $4.00 | $1.70M | $250.0K | 12 | 2025-05-20 |
| IVERIC bio, Inc. (ISEE) Delisted | Director | 22,088 | $39.95 | $882.4K | $0 | 6 | 2023-05-19 |
| IVERIC bio, Inc. (OPHT) Delisted | Director | 0 | — | — | $150.6K | 6 | 2018-07-11 |
| Allena Pharmaceuticals, Inc. (ALNA) Delisted | Director | — | $0.07 | — | $0 | 1 | 2018-06-12 |
| PTCT | Director | 20,000 | $62.84 | $1.26M | $300.0K | 1 | 2013-06-27 |
Recent Filings · Page 3 of 3
28 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-07-11 | IVERIC bio, Inc. (OPHT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-06-12 | Allena Pharmaceuticals, Inc. (ALNA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-05-22 | IVERIC bio, Inc. (OPHT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-01-23 | IVERIC bio, Inc. (OPHT) Delisted | Sell (S) | −6,000 | -$29.0K | EDGAR |
| 2016-06-07 | IVERIC bio, Inc. (OPHT) Delisted | Buy (P) | +3,500 | $199.4K | EDGAR |
| 2015-04-01 | IVERIC bio, Inc. (OPHT) Delisted | Buy (P) | +500 | $24.1K | EDGAR |
| 2013-10-07 | IVERIC bio, Inc. (OPHT) Delisted | Buy (P) | −2,000 | -$44.0K | EDGAR |
| 2013-06-27 | PTCT | Buy (P) | +20,000 | $300.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.